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Abstract
The main causes of death in osteosarcoma (OS) patients are the development of distant 
metastasis and resistance to chemotherapy. Clarification of the pathophysiological molec‐
ular mechanisms that contribute to the malignant phenotype in OS and identification of a 
molecular target, such as a diagnostic marker, prognostic predictor, or chemosensitivity 
sensor, are strongly desired to develop therapeutics for OS patients. Accumulating evi‐
dence has demonstrated that microRNAs (miRNAs), small endogenous single‐stranded 
noncoding RNAs, play critical roles not only in biological but also pathological processes 
such as cancer. miRNAs can function as oncogenes or tumor‐suppressive genes depend‐
ing on the mRNA they target. They are strongly associated with OS invasion, metastasis, 
and chemoresistance as well as OS cancer stemness. Furthermore, miRNAs are associ‐
ated with commonly altered genes, such as TP53 and RB1. Additionally, recent global 
microRNA expression analyses have identified specific miRNAs correlated with the 
clinical stage and the response to chemotherapy. In this chapter, we summarize the cur‐
rent understanding of the pathological roles of miRNAs as well as their potential utility 
as OS biomarkers.
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1. Introduction
Osteosarcoma (OS) is the most common primary malignant bone tumor. Before the 1970s, 
treatment generally included only surgical resection. However, because approximately 80% 
of patients have developed pulmonary metastases by the initial diagnosis, the 5‐year survival 
rate was 10–15% [1, 2]. Due to the development of multidrug chemotherapy, surgical wide 
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resection, and reconstruction with tumor prosthesis, the prognosis has gradually improved 
over the past 30 years [3]. Despite advances in multimodality treatment, the prognosis is still 
poor in patients with metastasis and/or acquisition of anticancer drug resistance. Because 
the critical molecular mechanisms contributing to the development of distant metastases and 
acquisition of chemoresistance in OS remain largely unknown, elucidation of the detailed 
pathophysiological molecular mechanisms is strongly desired to develop the novel tools for 
OS diagnosis, prognostic prediction, and treatment against OS.
microRNAs (miRNAs) are endogenous single‐stranded, noncoding RNAs with approximately 
22 nucleotides in length that regulate gene expression by cleavage or translational repression 
at the post‐transcriptional level by base pairing with the 3’ untranslated region (UTR) of their 
target mRNAs. To date, 2588 mature miRNAs have been identified, and they regulate the 
expression of more than a half of all human genes [4, 5]. Emerging evidence has demonstrated 
that miRNAs not only regulate biological processes such as development, differentiation, 
apoptosis, and proliferation but also modulate pathological conditions [6]. Genetic or epigene‐
tic alterations, dysregulation of transcription factors, and abnormal microRNA biogenesis can 
alter the dysregulation of microRNA expression [7]. As a result, the misexpressed microRNAs 
contribute to many types of human diseases, including cancer [6–8]. miRNAs can function 
as either oncogenes or tumor suppressors depending on their individual target mRNAs, and 
abnormal miRNA expression has been observed in various solid and hematopoietic tumors 
in relation to the initiation and progression of tumors including growth, metastasis, and drug 
resistance. Furthermore, miRNA expression profiling of human tumors has identified signa‐
tures associated with diagnosis, staging, progression, prognosis, and response to treatment.
After the first study examining the association between the microRNAs and OS pathogen‐
esis in 2009 [9], numerous studies have reported miRNA expression profiles from clinical 
OS samples and cell lines, and the association between miRNAs and malignant phenotypes. 
The altered gene expression previously reported in OS patients is closely association with 
altered miRNA expression. There is growing evidence that miRNAs play critical roles in vari‐
ous pathological processes, such as tumorigenesis, invasion, metastasis, chemoresistance, and 
cancer stem cell maintenance in OS [10, 11]. Therefore, altered miRNA expressions could be a 
useful diagnostic and prognostic tool for OS patients [10, 11].
Here, we summarize the pathological roles of miRNAs in OS and their potential value as 
diagnostic and prognostic biomarkers for OS patients.
2. Biological machinery and miRNA function
miRNAs are small, noncoding, single‐stranded RNAs 18–25 nucleotides long that regulate 
gene expression at the post‐transcriptional level. miRNAs are mainly transcribed by RNA 
polymerase II to generate primary‐miRNAs (pri‐miRNAs), which are usually 3–4 kb long and 
characterized by hairpin structures. In the nucleus, these pri‐miRNAs are cleaved into 70–100 
nucleotide precursor‐miRNAs (pre‐miRNAs) by Drosha and DGCR8 (DiGeorge Syndrome 
Critical Region Gene‐8). Pre‐miRNAs are transferred to the cytoplasm by Exportin‐5 and 
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cleaved to form a miRNA duplex by Dicer and TRBP (transactivating response RNA‐binding 
protein). The two miRNA strands of the duplex are processed into two different mature miR‐
NAs (‐3p or ‐5p). Mature miRNAs are incorporated into the RNA‐induced silencing complex 
(RISC), which contains Argonaute 2 (Ago2) and GW182. As a part of this complex, mature 
miRNAs suppress gene expression by binding to the 3′UTR of target mRNAs, which are rec‐
ognized by 6–8 nucleotides at the miRNA 5′‐terminus called seed sequence, leading to mRNA 
degradation or translation inhibition depending on the complementarity between the miRNA 
seed sequence and the 3′UTR of the mRNA (Figure 1) [7, 12].
3. miRNAs in cancer
The relationship between cancer and miRNAs was first reported in 2002. Calin et al. demon‐
strated that miR‐15 and miR‐16 at chromosome 13q14 were deleted or downregulated in the 
majority of chronic lymphocytic leukemia (CLL) cases and that these miRs induced apoptosis 
by direct suppression of Bcl‐2 (B cell lymphoma 2) in CLL cells [13, 14]. Genetic or epigen‐
etic changes, dysregulation of transcription factors, and abnormal microRNA biogenesis can 
alter microRNA expression [7]. Accumulating evidence suggests that dysregulated miRNAs 
induce cancer initiation and progression [6], and aberrant miRNAs can function as oncogenes 
or tumor suppressor genes depending on their target genes.
Figure 1. MicroRNA biological machinery. miRNAs are mainly transcribed by RNA polymerase‐II to generate pri‐
miRNAs. In the nucleus, pri‐miRNAs are cleaved into 70–100 nucleotide pre‐miRNAs by Drosha and DGCR8. Pre‐
miRNAs are transferred to the cytoplasm by Exportin‐5 and cleaved to form a miRNA duplex by Dicer and TRBP. The 
two miRNA strands of the duplex are processed into two different mature miRNAs (‐3p or ‐5p). Mature miRNAs are 
incorporated into the RISC, which contains Ago2. As a part of this complex, mature miRNAs suppress gene expression 
by binding to the 3′UTR of target mRNAs, which are recognized by 6–8 nucleotides at the miRNA 5′‐terminus called 
seed sequence, leading to mRNA degradation or translation inhibition.
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miRNA Target gene Function Reference
miR‐34a Surviving Proliferation, apoptosis, 
chemoresistance to CDDP
[21]
mTOR, MET, MDM4 Proliferation, apoptosis [17]
Eag1 Proliferation, tumor growth 
in vivo
[16]
CD44 Migration, invasion [22]
c‐Met Proliferation, migration, 
invasion, tumor growth and 
metastasis in vivo
[15]
miR‐143 Bcl‐2 Migration, invasion, apoptosis [20]
ATG2B, Bcl‐2, LC‐1,2 Proliferation, chemoresistance 
to DOX, autophagy, tumor 
growth in vivo
[23]
VCAN Migration, invasion [24]
MMP13 Invasion, metastasis [18]
Bcl‐2 Proliferation, apoptosis, 
tumorigenicity
[19]
miR‐144 ROCK1, ROCK2 Proliferation, invasion, 
tumorigenesis and metastasis 
in vivo
[25]
ROCK1 Proliferation, migration, 
invasion
[26]
Ezrin Invasion, metastasis [27]
TAGLN Proliferation, invasion [28]
miR‐145 FLI‐1 Proliferation, migration, 
apoptosis, tumor growth in vivo
[29]
ROCK1 Proliferation, migration, 
invasion
[30]
ROCK1 Proliferation, invasion [31]
VEGF Invasion, angiogenesis [32]
miR‐451 LRH‐1 Proliferation, cell cycle [33]
CXCL16 Proliferation, invasion [34]
PGE2, CCND1 Proliferation, cell cycle, 
apoptosis
[35]
Table 1. Tumor suppressive microRNAs and targets in osteosarcoma.
4. Dysregulation of microRNAs in OS
The relationship between OS and miRNA expression has been reported in over 400 publica‐
tions to date. Aberrantly expressed miRNAs have been shown to play essential roles in the 
biological processes of OS pathogenesis through the regulation of numerous protein‐coding 
genes and signaling pathways (Tables 1 and 2).
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miR‐34a: The overexpression of miR‐34a inhibited the proliferation, migration, and inva‐
sion of OS cell lines (SOSP‐9607 and Saos‐2) in vitro and decreased tumor growth and 
pulmonary metastasis of SOSP‐9607 cells in vivo by directly targeting c‐Met [15]. Based on 
a bioinformatics analysis, they demonstrated that miR‐34a had multiple putative targets 
associated with proliferation and metastasis, including members of the Wnt and Notch 
signaling pathways. Wu et al. demonstrated that miR‐34a was significantly downregu‐
lated in clinical OS tissues and cell lines. Overexpression of miR‐34a inhibited the pro‐
liferation of OS cells (MG‐63 and Saos‐2) in vitro and tumor growth in vivo by decreasing 
the expression of Ether à go‐go 1 (Eag1) [16]. Furthermore, Tian et al. demonstrated that 
miR‐34a inhibited proliferation and induced apoptosis in MG‐63 cells through the p53 
signaling pathway [17].
miR‐143: Osaki et al. compared HOS and 143B OS cells (highly metastatic variant of HOS 
transformed by v‐Ki‐ras) using a miRNA microarray analysis [18]. miR‐143 was significantly 
downregulated in 143B cells, and transfection of miR‐143 decreased cell invasiveness by 
directly targeting matrix metalloproteinase 13 (MMP13). Furthermore, the systemic admin‐
miRNA Target gene Function Reference
miR‐20a ERG2 Proliferation, cell cycle [37]
Fas Metastasis [36]
miR‐21 PTEN Proliferation, invasion, 
apoptosis
[39]
SPRY2 Migration, invasion [41]
Bcl‐2 Chemoresistance to CDDP [38]
RECK Invasion, migration [40]
miR‐135b FOXO1 Proliferation, invasion [42]
Myocardin Proliferation, migration, 
invasion
[43]
miR‐155 HBP1 Proliferation, cell cycle, tumor 
growth in vivo
[44]
– Proliferation, migration, 
invasion
[45]
– Autophagy, chemoresistance  
to DOX and CDDP
[46]
miR‐214 PTEN Proliferation, migration, 
invasion
[47]
PTEN Proliferation, apoptosis, 
tumorigenicity
[48]
LZTS1 Proliferation, invasion, tumor 
growth in vivo
[49]
Table 2. Ongogenic microRNA and targets in osteosarcoma.
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istration of miR‐143/atelocollagen complexes significantly suppressed the lung metastasis of 
143B in vivo. Zhang et al. demonstrated that the restoring miR‐143 expression reduced OS cell 
(MG‐63 and U‐2OS) viability, promoted apoptosis in vitro, and suppressed tumorigenicity 
in vivo [19], and they identified Bcl‐2, an important antiapoptotic protein, as a direct target 
of miR‐143. Li et al. also showed that miR‐143 promoted apoptosis in OS cells (MG‐63 and 
U‐2OS) through caspase‐3 activation by targeting Bcl‐2 [20]. Moreover, miR‐143 overexpres‐
sion significantly suppressed cell migration and invasion.
miR‐20a: Huang et al. found the higher miR‐20a expression in metastatic Saos‐2 cells com‐
pared with original Saos‐2 cells [36]. The metastatic cells expressed low levels of Fas, which is 
inversely correlated to lung metastasis, and miR‐20a directly regulated the expression levels 
of Fas. The inhibition of miR‐20a expression decreased the occurrence of metastasis in vivo. 
Ectopic expression of miR‐20a promotes the proliferation and cell cycle progression of Saos‐2 
cells by directly suppressing early growth response 2 (EGR2), a key regulator of proliferation 
and the cell cycle [37].
miR‐21: miR‐21 was significantly overexpressed in OS tissues compared with matched normal 
bone tissues [38], and miR‐21 knockdown reduced migration and invasion in MG‐63 cells 
by directly regulating RECK (reversion‐inducing‐cysteine‐rich protein with kazal motifs), 
a tumor suppressor gene. Lv et al. demonstrated that PTEN might be a potential target of 
miR‐21 [39]. The miR‐21 expression level was significantly higher in MG‐63 cells than in a 
human fetal osteoblastic cell line, hFOB1. 19, and miR‐21 overexpression increased prolifera‐
tive and invasive abilities and reduced apoptosis in MG‐63 cells. The authors suggested that 
miR‐21 activates the PI3K/Akt pathway by suppressing PTEN expression. In addition, miR‐21 
regulates the MAPK signaling pathway by targeting SPRY2 (protein sprout homolog 2), an 
antagonist of MEK1/2, as an oncogenic miRNA that increases cell proliferation, cell cycle pro‐
gression, and inhibits apoptosis [40].
5. miRNAs associated with dysregulated genes in OS
OS exhibits a broad range of genetic and molecular alterations, such as the gains, losses, or 
rearrangements of chromosomal regions that result in inactivation of tumor suppressor genes 
and the misregulation of major signaling pathways [50].
5.1. TP53‐associated miRNAs
TP53, located in 17q13.1, is a tumor suppressor gene that is mutated in more than 20% of 
human OS patients, which drives OS initiation and progression of OS [51]. Recent studies 
have demonstrated an association between TP53 and miRNAs. He et al. demonstrated that 
miR‐34s (miR‐34a, b, and c), which was decreased OS tissues and regulated by p53, affected 
the expression of CDK6, E2F3, Cyclin E2, and Bcl‐2, and induced G1 arrest and apoptosis 
partially in a p53‐dependent manner [9]. Novello et al. demonstrated that miR‐34a demeth‐
ylation by p53 was important for etoposide sensitivity [52]. They demonstrated that U2‐OS 
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cells either with the wild‐type p53 or a dominant‐negative form of p53 both of which were 
expressing increased levels of unmethylated miR‐34awere more sensitive to etoposide than 
p53‐deficient OS cells (MG‐63 and Saos‐2).
5.2. RB1‐associated miRNAs
RB1 on 13q14 is one of the most commonly inactivated genes in sporadic OS [53]. Poos et al. 
performed the miRNA expression analysis of OS cell lines based on their proliferative activity 
to generate a coregulatory network between miRNA and transcription factor. As a result, they 
found that downregulation of miR‐9‐5p, miR‐138, and miR‐214 was correlated to a strong 
proliferative phenotype in OS cells through their effect on NFKB and RB1 signaling pathways 
and focal adhesion molecules [54].
5.3. RUNX2‐associated miRNA
The chromosomal region 6p 12–21 is commonly amplified and DNA gains occur in 40–50% 
of tumors. This region contains RUNX2 which promotes terminal osteoblast differentiation 
and is elevated in conventional OS [53]. van der Deen et al. demonstrated that miR‐34c which 
is elevated by p53 and targets RUNX2, is absent in OS tissue [55]. This p53‐miR‐34c‐RUNX2 
pathway controls osteoblast growth and its alteration may impact on OS pathogenesis.
These data indicate that miRNAs play critical roles in OS pathogenesis by regulation of and 
interaction with commonly aberrant genes.
6. Cancer stem cell‐associated miRNAs
It is widely considered that cancer stem cell (CSC) populations possibly drive the refrac‐
tory nature of cancer, especially multidrug resistance and distant metastasis. OS stem cells 
have been isolated and identified by using cell sorting methods based on specific cell surface 
markers such as CD133, Hoechst dye side population assay, and sphere colony formation 
assays. Several groups have demonstrated that miRNAs are involved in the maintenance and 
stimulation of CSC population in various cancers, including OS [56]. miR‐29b‐1 expression 
was decreased in 3AB‐OS cells, a CSC line selected from MG‐63 cells, and its overexpres‐
sion causes cell proliferation, self‐renewal, and chemoresistance. This is accompanied by the 
downregulation of stem cell markers (Oct3/4, Sox2, Nanog, CD133, and N‐Myc), cell cycle‐
related markers (CCND2, E2F1, E2F2), and antiapoptotic markers (Bcl‐2 and IAP‐2) [57]. Xu 
et al. demonstrated a relationship between miR‐382 and CSCs in OS [58]. miR‐382 expression 
was significantly lower in highly metastatic OS cell lines and relapsed OS clinical samples. 
Likewise, the overexpression of miR‐382 decreased the CSC population defined by CD133 
and ALDH1 expression and osteosphere capacity. In vivo experiments showed that miR‐382 
overexpression inhibited CSC‐induced tumor formation. However, the association between 
miRNAs and CSCs is still under investigation, thus further research will be required to 
develop the novel therapeutic strategies targeting CSCs in OS.
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7. Chemoresistance‐associated miRNAs
Advances in chemotherapy have contributed to the dramatic improvement to OS patient 
outcomes. Most OS patients receive multidrug chemotherapy that consists of doxorubicin 
(DOX), cisplatin (CDDP), methotrexate (MTX), and ifosfamide (IFO), but certain population 
of OS patients exhibit chemoresistance. The molecular mechanisms driving poor response to 
chemotherapy remain largely unclear, and there are no biomarkers to discriminate between 
good and poor responders before chemotherapy.
DOX: miR‐301a expression promoted HMGCR expression by targeting AMP‐activated pro‐
tein kinase alpha 1 and enhanced the resistance of OS cells (U2OS, MG‐63) to DOX [59]. Chang 
et al. have demonstrated that miR‐101 overexpression dramatically reduces DOX‐induced 
autophagosome formation by suppressing autophagy 4 (Atg4) in U2‐OS cells, thereby enhanc‐
ing the sensitization of tumor cells to DOX [60]. miR‐184 expression was induced by DOX, 
and overexpression or silencing of miR‐184 reduced or enhanced DOX‐induced apoptosis by 
targeting Bcl‐2‐like protein 1 (BCL2L1) [61].
CDDP: Overexpression of miR‐224, which is downregulated in OS cell lines and tissues, con‐
tributed to the increased sensitivity of MG‐63 cells to CDDP by targeting Rac1 [62]. miR‐33a 
was upregulated in chemoresistant OS tissues and promoted resistance to CDDP in OS cell 
(MG‐63, Saos‐2) by downregulating TWIST [63]. Downregulation of miR‐497 induced CDDP 
resistance through the PI3K/Akt pathway by directly targeting VEGFA in human OS [64], and 
miR‐138 functions as a tumor suppressor by enhancing sensitivity to CDDP in OS via direct 
downregulation of EZH2 [65].
MTX: Decreased miR‐126 reduced the sensitivity to MTX and promoted apoptosis in OS cells 
(MG‐63 and U‐2OS) [66]. According to high‐throughput miRNA expression analysis, Song et 
al. demonstrated that miR‐140 expression was associated with chemosensitivity in OS tumor 
xenografts [67]. The authors showed that miR‐140 overexpression induced MTX resistance by 
targeting HDAC4 possibly through p53‐dependent manner. Furthermore, they proved that 
miR‐215 caused G2 arrest by suppressing DTL expression, and that led to chemoresistance 
against MTX [68].
IFO: Five miRNAs (miR‐92a, miR‐99b, miR‐132, miR‐193‐5p, and miR‐442a), which inhibit the 
TGF‐β and Wnt pathways by in silico analysis, discriminate good from poor IFO responders 
against IFO [69].
These reports suggest that miRNAs associated with an anticancer drug might be potential 
chemosensitivity biomarkers and promising therapeutic targets for OS patients.
8. Detection of miRNA in blood samples
There are few biomarkers for the diagnosis and prognosis prediction of OS patients other than 
alkaline phosphatase (ALP). Meta‐analysis has demonstrated that high ALP level is significantly 
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associated with a poor overall survival and event‐free survival rate and the presence of metasta‐
sis at diagnosis [70]. However, predictors of poor outcome are mainly clinical parameters, such 
as proximal extremity or axial skeleton involvement, large size/volume, detectable metastases 
at diagnosis, and poor response to preoperative chemotherapy [53]. Recently, growing evidence 
indicates the clinical usefulness of miRNAs as biomarkers, and numerous candidate miRNAs in 
blood samples have been reported in OS patients (Table 3).
Upregulated miRNAs in OS: The expression level of miR‐221 [71], miR‐27a [72], miR‐191 [73], 
and miR‐21 [74, 75] in blood samples was increased in OS patients compared with healthy 
controls, and compared to preoperation and postoperation state, the expression levels of miR‐
199a‐5p [76] and four miRNAs (miR‐195‐5p, miR‐199a‐3p, miR‐320a, and miR‐374a‐5p; [77]) 
were decreased in postoperative compared to preoperative blood samples. It has been sug‐
gested that upregulations of these miRNAs were significant predictors for poor overall and 
disease‐free survival. The expression levels of these miRNA were related to clinical stage 
[71–74], tumor size [73], distant metastasis [71–73, 75], and chemoresistance [50], the upregu‐
lations of these miRNAs were significant predictors for poor overall and disease‐free survival. 
miRNA Blood sample Reference
Upregulated miRNAs
 miR‐221 Serum [71]
 miR‐191 Serum [73]
 miR‐199a‐5p Serum [78]
 miR‐27a Serum [72]
 miR‐195‐5p, 199a‐3p, 320a, 374a‐5p Plasma [77]
 miR‐155 Serum [44]
 miR‐9 Serum [83]
 miR‐196a, 196b Serum [76]
 miR‐21 Serum [74]
Plasma [75]
Downregulated miRNAs
 miR‐223 Serum [79]
 miR‐106a‐5p, 16‐5p, 20a‐5p, 425‐5p, 
451a, 25‐3p, 139‐5p
Serum [84]
 miR‐195 Serum [80]
 miR‐133b, 206 Serum [82]
 miR‐34b Plasma [81]
 miR‐199a‐3p, 143 Plasma [75]
Table 3. Dysregulated miRNAs in blood samples of OS patients.
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In addition, the combination of dysregulated miRNAs was more accurate than the individual 
expression level of each miRNA. The coexpression of miR‐196a/miR‐196b [78] and the com‐
bination of four miRNAs (miR‐195‐5p, miR‐199a‐3p, miR‐320a, and miR‐374‐5p) [77] were 
superior predictors to any of the miRNAs alone.
Downregulated miRNAs in OS: In contrast, the expression level of miR‐223 [79], miR‐195 [80], 
and miR‐34b [81] in blood samples was significantly decreased in OS patients compared to 
healthy controls. These miRNAs levels were associated with clinical stage [79, 80] and dis‐
tant metastasis [79–81], and the decreased expression of these miRNAs was associated with 
shorter overall survival and disease‐free survival. In addition, the coexpression of miR‐133b/
miR‐206 was a prognostic factor for overall survival and disease‐free survival [82].
These data indicate the potential of miRNAs in blood samples as diagnostic markers, prog‐
notic predictors, and chemosensitivity sensors.
9. Conclusion
Dysregulated miRNAs contribute to the initiation and progression of human OS in several 
pathobiological aspects. The detection of aberrant miRNAs could be a versatile tool for 
diagnosis, prognosis and chemosensitivity judgment, and inhibition of oncogenic miRNAs 
and/or restoration of tumor‐suppressing miRNAs could be a novel strategy for treatment 
of OS.
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